H.C. Wainwright initiated coverage of Lexaria Bioscience with a Buy rating and $10 price target. The company has drug delivery platform that enhances bioavailability of FDA-approved active pharmaceutical ingredients. The firm says DehydraTECH-GLP-1 drugs are de-risked from a commercial perspective.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX: